dafa大发手机app-dafa手机客户端

025-52457056
团队实力再升级,dafa大发手机app建立定量药理团队!
时间:2021-04-22 14:25 点击次数:
热烈欢迎
中国药科大学刘李博士
作为首席技术官加入
dafa大发手机app生物大家庭
带领我司定量药理团队
更加专业、高效、稳定的建设及发展
 

 

2021年4月1日,dafa大发手机app生物迎来了崭新的一页,我们有幸邀请到中国药科大学定量药理学专家,博士生导师刘李教授加盟dafa大发手机app大家庭,并作为我们的首席技术官(CTO),负责运营及管理新成立的定量药理部门,为我们的客户提供更全面的技术服务。后续在刘李教授的带领下,借助于dafa手机客户端及dafa大发手机app生物平台资源,着重建立体内体外的数据模拟平台——解决生物等效性结果预测及豁免的瓶颈;着重建立创新药动物数据预测人体药代特征模拟平台——解决创新药早期临床剂量准确性难题;着重建立生理药动学PBPK的建模与模拟,加速创新药的临床早期开发。
 

刘李教授简介
 

刘李,教授,博士生导师,江苏省“青蓝工程”学术带头人、“333工程”第三层次和“六大人才高峰”培养对象。现任中国药科大学药学院药理系副主任,中国药理学会药物代谢专业委员会理事和青委会副主任委员兼秘书长。专业方向为药物代谢动力学,具体研究方向为:疾病状态下代谢酶和转运体功能与表达调控、创新药物药物代谢动力学和定量药理学。主持多项国家自然科学基金和多项省部级项目,以第一和通讯作者共发表SCI论文60余篇。
 
定量药理学研究方向的代表性论著(通讯作者)
Xu R, Kong W, An X, Zou J, Liu L, Liu X. Physiologically-based pharmacokinetic-pharmacodynamics model characterizing CYP2C19 polymorphisms to predict clopidogrel pharmacokinetics and its anti-platelet aggregation effect following oral administration to coronary artery disease patients with or without diabetes. Front Pharmacol. 2020; 11: 593982.
Li P, Huang J, Geng D, Liu P, Chu Z, Zou J, Yang G, Liu L. Semi-mechanistic modeling of HY-021068 based on irreversible inhibition of thromboxane synthetase. Front Pharmacol. 2020; 11: 588286.
Yang Y, Li P, Zhang Z, Wang Z, Liu L, Liu X. prediction of cyclosporin-mediated drug interaction using physiologically based pharmacokinetic model characterizing interplay of drug transporters and enzymes. Int J Mol Sci. 2020; 21(19):7023.
Kong WM, Sun BB , Wang ZJ, Zheng XK, Zhao KJ, Chen Y, Zhang ZX, Liu PH, Zhu L, Xu RJ, Li P, Liu L, Liu XD. Physiologically based pharmacokinetic-pharmacodynamic modeling for prediction of vonoprazan pharmacokinetics and its inhibition on gastric acid secretion following intravenous/oral administration to rats, dogs and humans. Acta Pharmacol Sin. 2020; 41(6):852-865. 
Wang Z, Yang H, Xu J, Zhao K, Chen Y, Liang L, Li P, Chen N, Geng D, Zhang X, Liu X, Liu L. Prediction of atorvastatin pharmacokinetics in high-fat diet and low-dose streptozotocin induced diabetic rats using a semi-physiologically based pharmacokinetic model involving both enzymes and transporters. Drug Metab Dispos. 2019; 47(10):1066-1079.
Qian CQ,  Zhao KJ, Chen Y, Liu L, Liu XD. Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/Pglycoprotein to healthy human using a semi-physiologicallybased pharmacokinetic model involving both enzyme and transporter turnover. Eur J Pharm Sci. 2019; 134: 194-204.
Wang S, Tang X, Yang T, Xu J, Zhang J, Liu X, Liu L. Predicted contributions of cytochrome P450s to drug metabolism in human liver microsomes using relative activity factor were dependent on probes. Xenobiotica. 2019; 49(2): 161-8.
Chen Y, Zhao K, Liu F, Li Y, Zhong Z, Hong S, Liu X, Liu L. Predicting Antitumor Effect of Deoxypodophyllotoxin in NCI-H460 Tumor-Bearing Mice on the Basis of In Vitro Pharmacodynamics and a Physiologically Based Pharmacokinetic-Pharmacodynamic Model. Drug Metab Dispos. 2018; 46(6): 897-907.
Chen Y, Zhao K, Liu F, Xie Q, Zhong Z, Miao M, Liu X, Liu L. Prediction of Deoxypodophyllotoxin Disposition in Mouse, Rat, Monkey, and Dog by Physiologically Based Pharmacokinetic Model and the Extrapolation to Human. Front Pharmacol. 2016; 7: 488.
Li J, Guo HF, Liu C, Zhong Z, Liu L, Liu XD. Prediction of Drug Disposition in Diabetic Patients by Means of a Physiologically Based Pharmacokinetic Model. Clin Pharmacokinet. 2015; 54(2): 179-93.
Guo H, Liu C, Li J, Zhang M, Hu M, Xu P, Liu L, Liu X. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions. J Pharm Sci. 2013; 102(8): 2819-36.

苏ICP备17060201号-1 dafa手机客户端 版权所有,未经允许不得转载!